Cantor Fitzgerald set a $112.00 target price on Celgene (NASDAQ:CELG) in a research report report published on Wednesday. The firm currently has a hold rating on the biopharmaceutical company’s stock.
“The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own.”,” the firm’s analyst commented.
Several other equities research analysts have also recently weighed in on the company. Mizuho restated a buy rating and set a $128.00 target price on shares of Celgene in a research note on Wednesday. Guggenheim restated a buy rating and set a $147.00 target price on shares of Celgene in a research note on Wednesday, January 10th. Zacks Investment Research upgraded Celgene from a sell rating to a hold rating in a research note on Monday, January 8th. SunTrust Banks set a $127.00 price target on Celgene and gave the stock a buy rating in a research report on Monday, January 8th. Finally, Credit Suisse Group set a $125.00 price target on Celgene and gave the stock a buy rating in a research report on Monday, January 8th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Celgene currently has an average rating of Buy and an average price target of $129.98.
Celgene (NASDAQ:CELG) traded up $0.93 during mid-day trading on Wednesday, reaching $102.65. The company had a trading volume of 8,098,686 shares, compared to its average volume of 6,610,000. The stock has a market capitalization of $81,560.00, a PE ratio of 24.21, a price-to-earnings-growth ratio of 0.65 and a beta of 1.77. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.58 earnings per share. research analysts predict that Celgene will post 6.7 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Grisanti Capital Management LLC purchased a new stake in shares of Celgene in the second quarter valued at $3,616,000. RiverPoint Capital Management LLC lifted its position in shares of Celgene by 3.1% in the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after acquiring an additional 3,680 shares in the last quarter. LSV Asset Management acquired a new position in Celgene in the second quarter valued at $1,701,000. Spectrum Management Group Inc. acquired a new position in Celgene in the second quarter valued at $462,000. Finally, Polen Capital Management LLC increased its stake in Celgene by 7.7% in the second quarter. Polen Capital Management LLC now owns 5,082,991 shares of the biopharmaceutical company’s stock valued at $660,128,000 after purchasing an additional 363,108 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/20/cantor-fitzgerald-analysts-give-celgene-celg-a-112-00-price-target.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.